Watts Gwilliam & Co. LLC Makes New Investment in Eli Lilly and Company (NYSE:LLY)

Watts Gwilliam & Co. LLC acquired a new position in Eli Lilly and Company (NYSE:LLY) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 1,592 shares of the company’s stock, valued at approximately $1,455,000.

Other large investors have also added to or reduced their stakes in the company. Capital Planning LLC bought a new position in shares of Eli Lilly and Company during the 1st quarter valued at approximately $262,000. CHURCHILL MANAGEMENT Corp bought a new position in shares of Eli Lilly and Company during the 1st quarter valued at approximately $6,916,000. M&G Plc bought a new position in shares of Eli Lilly and Company during the 1st quarter valued at approximately $8,896,000. HighPoint Advisor Group LLC bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at approximately $9,878,000. Finally, Leo Wealth LLC bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at approximately $3,355,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 1.0 %

Shares of NYSE LLY opened at $910.69 on Friday. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. The stock has a market capitalization of $865.55 billion, a P/E ratio of 112.15, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. Eli Lilly and Company has a 1-year low of $547.61 and a 1-year high of $972.53. The business has a fifty day moving average price of $908.28 and a 200 day moving average price of $851.21.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The company had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Equities research analysts expect that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on LLY. Berenberg Bank boosted their target price on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Guggenheim upped their price objective on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research report on Friday, August 16th. BMO Capital Markets upped their price objective on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Evercore ISI raised Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Finally, Truist Financial upped their price objective on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research report on Thursday. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $979.29.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.